Related Articles
Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model
Synergistic antitumor effect of the anti‑ErbB2 antibodies trastuzumab and H2‑18 on trastuzumab‑resistant gastric cancer cells
Pertuzumab for the treatment of patients with human epidermal growth factor receptor 2‑positive breast cancer in Japan
Role for HER2/neu and HER3 in fulvestrant-resistant breast cancer
Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models